Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients.

Trial Profile

Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nevirapine
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms KANELA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 May 2009 Planned end date changed from 1 Mar 2011 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 100 to 9 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top